Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrEAsT: BN-Brachyury, Entinostat, T-DM1, M7824 in Advanced Breast Cancer
NCT04296942Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bintrafusp alfa, MVA-BN-brachyury + FPV-brachyury and entinostat in breast cancer (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate at 17 days and Incidence of Adverse Events at 17 days. Started May 2021; status: terminated.
02
Drugs
bintrafusp alfaMVA-BN-brachyury + FPV-brachyuryentinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04296942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296942.